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indirect comparison techniques. METHODS: All twelve-week randomised con-
trolled trials of olanzapine, quetiapine and aripiprazole conducted in monotherapy
or in adjunct therapy were identified through a literature review. Five mono-
therapy studies were found, allowing the comparison of asenapine versus quetia-
pine and aripiprazole, with olanzapine and haloperidol as common references,
using Bucher’s method (Bucher et al., J Clin Epidemiol 1997). One twelve-week and
four six-week placebo-controlled adjunctive therapy trials were identified, en-
abling the comparison of asenapine to olanzapine, quetiapine and aripiprazole
through pairwise comparisons using placebo as a common reference. The out-
comes used for comparison were the Young Mania Rating Scale (YMRS) change
from baseline, YMRS response and remission rates. RESULTS: In monotherapy,
the differences of mean YMRS change from baseline to week 12 between
asenapine versus quetiapine and aripiprazole were 0.10 (p0.959) and 1.76
(p0.342), respectively. Relative risks for response and remission were close to
one. In adjunct therapy, the differences of mean YMRS change from baseline to
week 6 between asenapine versus olanzapine, quetiapine and aripiprazole were
0.63 (p0.656), 0.10 (p0.967) and -0.10 (p0.946), respectively. Relative risks for
response and remission were numerically in favour of asenapine but not statis-
tically significant. CONCLUSIONS: The results of these indirect comparisons con-
sistently showed comparable efficacy of asenapine versus the investigated atypical
antipsychotics.
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OBJECTIVES: Reducing hospital readmission rates has emerged as an important
strategy for increasing the quality of health care, while reducing the cost of care. An
analysis was conducted using an US government-funded tool to investigate the
impact of post-hospitalization follow-up on readmissions for depression.
METHODS: Public (Medicare) and proprietary (MarketScan Commercial, Medicare
Supplemental and Medicaid) administrative databases were standardized and
linked via a common data model. A web-based tool was developed that captured
the logic typically required by CER methods, e.g. searches on drugs, diagnoses, and
procedures, application of time constraints, and development of variables for in-
tervention, outcomes and covariates. Patients with a hospitalization for depression
and was discharged to home were selected. Additional inclusion criteria were a
minimum of one year of enrollment prior to and 60 days of enrollment following
discharge. Patient claims histories were searched to determine outpatient visits
with 7 and 30 days post-discharge and rehospitalization within 30 days post-dis-
charge. SAS procedures embedded in the tool were utilized for bivariate and mul-
tivariate analyses. RESULTS: The study included 39,985 patients. Patients with a
follow-up visit were slightly older and were more likely to be female. Prior to index
hospitalization, patients with follow-up were more likely to have filled an antide-
pressant or antianxiety medication and had a diagnosis of depression or anxiety
pre-index hospitalization. Little difference was found in the rate of pre-period
hospitalization. A logistic regression model found that having a follow-up visit
within 7 days of discharge was negatively and statistically significantly associated
with having a readmission within 30 days (odds ratio  0.88, CI0.80 – 0.97, once
other factors (demographics, diagnosis, and drug treatment) were controlled.
CONCLUSIONS: The data model and tool may be leveraged in a similar manner to
compare drug and medical treatment options more rapidly and efficiently.
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OBJECTIVES: Few studies of mental illness in Africa have centered on Alzheimer’s
disease. The primary aim of the study was to determine the prescribing patterns
and cost of drugs for Alzheimer’s disease in a South African private health care
sector patient population. METHODS: A retrospective drug utilization study was
conducted. Data were obtained from a South African private medical aid adminis-
trator for 2010. The database consisted of 2,126,264 records for medication and
procedures.RESULTS:A total of only 25 patients (13 females and 12 males) received
114 medicine items for Alzheimer’s disease at a cost of R70 794.11 (average cost per
item R621.00 (SDR208.73)). This medicine is relatively expensive, yet not all med-
ical aid schemes pay for medication for Alzheimer’s disease. The average age of
patients was 72.52 (SD10.03) years, with ages ranging from 46 to 88 years. Me-
mantine was the most frequently prescribed active ingredient (42.98% of prescrib-
ing frequency and 46.35% of cost), followed by donepezil (40.35% of frequency and
41.59% of cost). The average cost per memantine prescription was R669.61, fol-
lowed by R640.12 for donepezil and R449.35 for galantamine. The different medical
aids only paid, on average, 78.86% of the total amount claimed by patients for these
medicines. Most products were claimed between February and June 2010. Average
Prescribed Daily Doses (PDDs) of active ingredients were generally lower than their
respective Defined Daily Doses (DDDs). The average PDD for memantine was 18.27
mg (DDD20 mg), for donepezil was 7.07 mg (DDD7.5 mg) and for galantamine
was only 6.95 mg (DDD16 mg). Most prescriptions for memantine (75.51%) were
prescribed in its PDD of 20 mg. CONCLUSIONS: The results were generally similar
to those of previous South African studies. Studies on larger patient populations
are necessary to investigate the cost-effectiveness of the different treatment
options.
PMH10
EXPOSURE TO ANTIPSYCHOTIC MEDICATIONS DURING FOUR YEAR PERIODS
FOLLOWING TREATMENT INITIATION AMONG CHILDREN UNDER SIX YEARS
OLD
Constantine RJ, Jentz S, McPherson M
University of South Florida, Tampa, FL, USA
OBJECTIVES: In short term clinical trials antipsychotic medications are well toler-
ated by children under six years old. While concerns have been raised about the
impact of long term exposure on metabolic and cardiovascular health and on the
developing brain, little is known about the extent of long term antipsychotic expo-
sure in this age group. This study quantifies antipsychotic exposure over a 4 year
period of children who began antipsychotic treatment before their sixth birthday
and identifies the variables associated with the risk of long term exposure.
METHODS: Children were identified who initiated an index episode of antipsy-
chotic treatment before their sixth birthday in Florida’s fee for service Medicaid
program. Using claims data the medication utilization of these children was
tracked during the year before and the four years following the start of their index
episodes (pre-index and four post-index periods). Generalized estimating equa-
tions were used to identify variables associated with the risk of additional days of
antipsychotic exposure. RESULTS: Five hundred twenty-eight children were in-
cluded in the cohort. The mean total days of exposure was 821.9 (431.9) repre-
senting 56.3 % of all days during the four post-index periods. The mean days of
exposure to combinations of antipsychotics and other classes of psychotherapeu-
tic medications were 623.8 447.6 days. Children with primary diagnoses of per-
vasive developmental disorders and affective disorders were at greater risk of ad-
ditional days of exposure than children with ADHD. Exposure tended to be greater
among children with indicators of clinical complexity including the presence of
secondary diagnoses and the use of other classes of psychotherapeutic medica-
tions in addition to antipsychotics. CONCLUSIONS: Exposure to antipsychotic me-
diations was extensive. Although these children may have had complex and severe
problems, additional research is urgently needed on the benefits and risks of long
term antipsychotic exposure among very young children.
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OBJECTIVES: Up to one-third of older adults fall each year with medications rep-
resenting a well-known risk factor for falling. Ultimately, falls that result in injury
are the true target of fall prevention and are of interest to healthcare practitioners.
Therefore, this meta-analysis focused on evaluating the association of antipsy-
chotic and antidepressant drugs with hip fracture, a common and debilitating
fall-related injury. METHODS: A search of Pubmed/Medline was conducted from
1966-2010 with key words including “antipsychotic agents”, “psychotropic drugs”,
“antidepressive agents”, “aged”, and “hip fracture”. Inclusion criteria included
mean age 65 years and statistical adjustment or stratification by age and gender.
Excluded were studies where hip fractures were not distinguished from other frac-
ture types or authors failed to answer queries for required information. A random
effects model was used to calculate summary odds ratios for the specific classes of
psychotropic medications. RESULTS: Of 166 studies identified, 10 antipsychotic-
related studies and 14 antidepressant-related studies met the inclusion criteria.
Combined, these studies represent over 70,000 hip fracture cases and approxi-
mately 272,000 total subjects from eight different nations and four continents.
Summary odds ratios include (95% confidence interval): conventional antipsychot-
ics 1.68 (1.43, 1.99), atypical antipsychotics 1.30 (1.14, 1.49), tricyclic anti-depres-
sants 1.71 (1.43, 2.04), and selective serotonin re-uptake inhibitors 1.94 (1.37, 2.76).
Although some studies reported drug-specific risk measures, the availability of
drug-specific data was limited. CONCLUSIONS: All classes considered in this anal-
ysis are associated with an increased risk of hip fracture in older adults. There is a
trend towards reduced risk associated with atypical antipsychotics compared to
conventional antipsychotics, although this does not reach statistical significance.
To minimize the risk of hip fracture in older adults requiring psychotropic medi-
cations, further research examining the association of hip fractures to specific
drugs within these classes is essential.
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OBJECTIVES: This post-hoc analysis assessed the risk and the factors associated
with relapse and hospitalizations during the 2-year treatment of outpatients
treated with oral olanzapine or olanzapine long-acting injection (LAI). METHODS:
We used data of a 104-week multicenter, effectiveness study comparing oral and
LAI olanzapine in the treatment of outpatients with schizophrenia (n524;
NCT00320489). Relapse was defined as hospitalization for schizophrenia; a 25%
increase from baseline on the PANSS total score (if baseline score 40), a 10 point
increase (if baseline score 40); a 1-point increase from baseline on the CGI-S
scale, provided that final CGI-S score was 4; deliberate self-injury or injury to
others that is associated with worsening of psychosis; or discontinuation from the
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